Navigation Links
Delivering drugs to the brain: New research into targeted treatment of Alzheimer's
Date:12/7/2010

opening these pathways into the brain can be found within the natural world. He will utilize this new research funding to investigate how certain natural pathogens cross the blood-brain barrier, and how he can develop synthetic small molecules that mimic the same blood-brain breech.

The end goal of the research is to develop small molecules that act as "chemical wedges," which "sit" on the Velcro junction points within the brain's blood vessels to prevent them from closing and gently allowing drugs to move through the system. His research seeks to develop a chemical method to open the blood-brain barrier that is gentle, but also quickly reversible.

The new technique would not be without risk, but the payoff of such a therapy would be broad, according to Karande.

"The most important challenge is going to be how we control this," he said. "We want to gently open the junctions in the brain, allow them to stay open for a short period of time during the delivery of a drug, and then reseal before any other potentially harmful materials can cross the barrier."

The result would be a much more targeted delivery of drugs to the brain. Currently, some of the most widely administered drugs used for people with brain illness do cross the blood-brain barrier, but only when large concentrations of chemicals are administered into the body to ensure that just a small fraction of the drug will bypass the tight blood-brain barrier. An example of this is the common Parkinson's drug L-DOPA, which is used to successfully treat thousands of people, but at the cost of substantial side effects due to the significant levels of the drug required to make it into the brain, according to Karande. He hopes his research success will allow drugs like L-DOPA and others to be more efficiently used within the body.

"We want to saturate the brain with a drug treatment," he said. Such saturation in the brain would reduce the presence of the drug in other hea
'/>"/>

Contact: Gabrielle DeMarco
demarg@rpi.edu
518-956-0701
Rensselaer Polytechnic Institute
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Molecules delivering drugs as they walk
2. Conserving nature and dollars: Delivering cost-effective biodiversity protection
3. Study shows that delivering stem cells improves repair of major bone injuries in rats
4. Delivering medicine directly into a tumor
5. Synthetic cells shed biological insights while delivering battery power
6. Preventing ear infections in the future: Delivering vaccine through the skin
7. HIV drugs interfere with blood sugar, lead to insulin resistance
8. Multiple sclerosis drug serves as model for potential drugs to treat botulism poisoning
9. Scientists learn more about how kidneys fail and how new drugs may intervene
10. Drugstore of the future -- new drugs from an old source
11. Video-game technology may speed development of new drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)... Dec. 9, 2014  Valencell, a leader in performance ... a staggering demand from its licensees for highly accurate, ... is not solely coming from fitness and health sectors, ... "A wearable is only as useful as the ... the ultimate driver in long-term mass consumer adoption of ...
(Date:12/10/2014)... , December 9, 2014 ... BCARD Platform   ... meeting scheduling solutions for business-to-business (B2B) events, today ... leader in mobile near-field communication (NFC), Bluetooth low ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will ...
(Date:12/3/2014)... 2, 2014   Marvin Test Solutions , ... solutions for military, aerospace, and manufacturing organizations, today ... successful TS-900 PXI semiconductor test platform . ... high-end systems to customers at a fraction of ... traditional ATE. "Our semiconductor customers ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... A team of researchers from the Hawai,i Institute ... map of corals and zooxanthellae as part of a ... provides global-scale biological and ecosystem information on symbiotic zooxanthellae ... that live inside the cells of other marine organisms ...
... University of Maryland School of Medicine researchers have uncovered ... understanding cardiac arrhythmia and other heart muscle problems. Understanding ... open the door to new treatments. The study, published ... electrical impulses that coordinate contraction in heart and skeletal ...
... Scientists are reporting the development and successful tests in humans ... from exhaled breath, an advance that they describe as a ... non-invasive test for MS -- the most common neurological disease ... ACS Chemical Neuroscience . Hossam Haick and colleagues report ...
Cached Biology News:An online global map of coral and zooxanthellae data for climate change study is released 2An online global map of coral and zooxanthellae data for climate change study is released 3UM School of Medicine finds new pathway critical to heart arrhythmia 2UM School of Medicine finds new pathway critical to heart arrhythmia 3Advance toward a breath test to diagnose multiple sclerosis 2
(Date:12/13/2014)... December 13, 2014 QuickSTAT is making ... and Cold Chain capabilities, and is delighted to announce ... France, to serve Life Science clients in the region. ... a controlled-ambient warehouse, will provide 24/7 transportation and logistics ... investigational drugs, patient-clinical specimens, API, following IATA rules and ...
(Date:12/13/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/6p4j9m/glucose_sensors ) ... Sensors: the Next Generation" report to their ... The convergence of small-scale electronics and ... a better future to millions of diabetes patients ... levels accurately and reliably have the capability to ...
(Date:12/13/2014)... and SAN ANTONIO , Dec. ... today announced the presentation of data at the San ... EPO-ANE-3010 study evaluating epoetin alfa plus best supportive care ... patients with metastatic breast cancer receiving standard chemotherapy. This ... was to rule out a 15 percent or greater ...
(Date:12/12/2014)... 2014 Graphite Metallizing Corporation, the manufacturer ... and process equipment, has appointed Kirk Staller as Sales ... Canada. Staller holds a B.S. degree from Purdue University ... market place, much of it with a manufacturer of ... Michigan office. , “We are pleased to ...
Breaking Biology Technology:Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2Glucose Sensors: the Next Generation 2Glucose Sensors: the Next Generation 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12Kirk Staller Joins Graphite Metallizing Corporation 2
... 2012 , Point-of-Care Diagnostics Initiative is ... by Bill & Melinda Gates Foundation and Grand Challenges Canada ... aid effort to create a low-cost portable testing platform for ... Development expected to be completed by 2014, enabling rapid ...
... 3, 2012 Profil® Institute for Clinical Research, Inc., ... diabetes and obesity, announced today record growth in the ... also reports an increase in the number of mid-size ... the largest global pharmaceutical companies, driven by a strong ...
... Therapeutics Plc (AIM: SLN), a leading international RNAi ... , has announced it has amended its existing exclusive Licensing ... a Phase 2a clinical study to assess the effect of ... patients with moderate and advanced Open-Angle Glaucoma (OAG). PF-655 incorporates ...
Cached Biology Technology:QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to World's Poorest Countries 2QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to World's Poorest Countries 3QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to World's Poorest Countries 4QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to World's Poorest Countries 5Profil Institute Reports Record Growth in Number of Clinical Trials in the Pipeline 2Profil Institute Reports Record Growth in Number of Clinical Trials in the Pipeline 3Silence Therapeutics' Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication 2Silence Therapeutics' Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication 3Silence Therapeutics' Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication 4Silence Therapeutics' Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication 5
Rabbit polyclonal to Somatostatin 28 ( Abpromise for all tested applications). entrezGeneID: 6750 SwissProtID: P61278...
... well Magnetic-Ring Stand is designed for paramagnetic ... microplates. The stand has a plastic base ... plate footprint. The use of 96 extremely ... easy magnetic separation. With this magnetic stand, ...
... DNA polymerase from Thermus aquaticus expressed in ... 1 tube of 250 units enzyme/tube and ... DNA), is the same enzyme as AmpliTaq ... a proprietary separation process to ensure that ...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
Biology Products: